2024
HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease
Adler J, Galanko J, Ammoury R, Benkov K, Bousvaros A, Boyle B, Cabrera J, Chun K, Dorsey J, Ebach D, Firestine A, Gulati A, Herfarth H, Jester T, Kaplan J, Leibowitz I, Linville T, Margolis P, Minar P, Molle-Rios Z, Moses J, Olano K, Pashankar D, Pitch L, Saeed S, Samson C, Sandberg K, Steiner S, Strople J, Sullivan J, Wali P, Kappelman M. HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease. The American Journal Of Gastroenterology 2024, 120: 1076-1086. PMID: 39423015, DOI: 10.14309/ajg.0000000000003135.Peer-Reviewed Original ResearchHLA-DQA1*05Anti-drug antibodiesDQA1*05Anti-drug antibody developmentTreatment failureCrohn's diseaseAnti-TNFPositive patientsDevelopment of anti-drug antibodiesAnti-TNF treatment failureTumor necrosis factor antagonistsIndicator of treatment failureAnti-TNF monotherapyPediatric Crohn's diseaseIncreased treatment failureTrial of childrenYears of ageRandomized trial of childrenOral methotrexatePositive participantsRisk stratificationPediatric dataRandomized trialsIncreased riskPrimary outcome
2023
Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn’s Disease: A Pragmatic Randomized Trial
Kappelman M, Wohl D, Herfarth H, Firestine A, Adler J, Ammoury R, Aronow J, Bass D, Bass J, Benkov K, Tobi C, Boccieri M, Boyle B, Brinkman W, Cabera J, Chun K, Colletti R, Dodds C, Dorsey J, Ebach D, Entrena E, Forrest C, Galanko J, Grunow J, Gulati A, Ivanova A, Jester T, Kaplan J, Kugathasan S, Kusek M, Leibowitz I, Linville T, Lipstein E, Margolis P, Minar P, Molle-Rios Z, Moses J, Olano K, Osaba L, Palomo P, Pappa H, Park K, Pashankar D, Pitch L, Robinson M, Samson C, Sandberg K, Schuchard J, Seid M, Shelly K, Steiner S, Strople J, Sullivan J, Tung J, Wali P, Zikry M, Weinberger M, Saeed S, Bousvaros A. Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn’s Disease: A Pragmatic Randomized Trial. Gastroenterology 2023, 165: 149-161.e7. PMID: 37004887, PMCID: PMC10330864, DOI: 10.1053/j.gastro.2023.03.224.Peer-Reviewed Original ResearchConceptsPediatric Crohn's diseaseNecrosis factor inhibitorsPatient-reported outcomesAdverse eventsTreatment failureCombination therapyCrohn's diseaseSerious AEsFactor inhibitorsTumor necrosis factor inhibitorsAnti-drug antibody developmentAnti-TNF monotherapyCombination therapy armCrohn's disease therapyMethotrexate combination therapyTolerable safety profileLow-dose methotrexateMore adverse eventsSerious adverse eventsAnti-drug antibodiesPragmatic Randomized TrialDisease therapyLoss of responseOral methotrexateTherapy arm
2022
Susceptibility of Patients with Inflammatory Bowel Disease to COVID-19 Compared with Their Households
Anushiravani A, Saberzadeh-Ardestani B, Vahedi H, Fakheri H, Mansour-Ghanaei F, Maleki I, Nasseri-Moghaddam S, Vosoghinia H, Ghadir M, Hormati A, Kasaeian A, Radmard A, Khosravi B, Malekzadeh M, Alatab S, Sadeghi A, Aminisani N, Poustchi H, Sima A, Malekzadeh R. Susceptibility of Patients with Inflammatory Bowel Disease to COVID-19 Compared with Their Households. Middle East Journal Of Digestive Diseases 2022, 14: 182-191. PMID: 36619152, PMCID: PMC9489316, DOI: 10.34172/mejdd.2022.271.Peer-Reviewed Original ResearchInflammatory bowel diseaseAnti-TNF monotherapySevere inflammatory bowel diseasePrevalence of COVID-19Susceptibility of patientsSeverity of inflammatory bowel diseaseTreatment of inflammatory bowel diseaseData of patientsMultivariate logistic regressionFrequency of COVID-19Immunosuppressive agentsRisk of coronavirus disease 2019Associated with COVID-19Multivariate analysisMulti-centerBowel diseasePatientsRisk factorsObservational studyCoronavirus disease 2019Effects of ageMonotherapyLogistic regressionCOVID-19 susceptibilityPrevalence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply